Takeda Pharmaceutical (TAK) Net Income Growth (1y) (2018 - 2026)
Takeda Pharmaceutical (TAK) Net Income Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -384.49% |
| 5 | United Therapeutics | 23.01 Bn | 20.86 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.02 Bn | 22.02 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.59 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.74 Bn | 12.31 Bn | 785.00 Mn | -14.93% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | -562.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384.49% |
| Dec 31, 2025 | -252.45% |
| Sep 30, 2025 | 17.15% |
| Jun 30, 2025 | -3.67% |
| Mar 31, 2025 | 2.31% |
| Dec 31, 2024 | -4,440.99% |
| Sep 30, 2024 | 22.10% |
| Jun 30, 2024 | -13.31% |
| Mar 31, 2024 | -21.06% |
| Dec 31, 2023 | -96.58% |
| Sep 30, 2023 | 297.92% |
| Jun 30, 2023 | -17.21% |
| Mar 31, 2023 | -41.30% |
| Dec 31, 2022 | -11.55% |
| Sep 30, 2022 | -30.17% |
| Jun 30, 2022 | -43.45% |
| Mar 31, 2022 | 232.37% |
| Dec 31, 2021 | -37.42% |
| Sep 30, 2021 | 648.22% |
| Jun 30, 2021 | 70.07% |